Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randall J Bateman

Showing results (381-390 of 391) with videos related to

Pageof 40
Sort By:
Neurology|January 26, 2021
Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Guoqiao Wang, Kejal Kantarci, et al.
Nature Neuroscience|July 10, 2023
Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)Nicole S McKay, Brian A Gordon, Russ C Hornbeck, et al.
Molecular Psychiatry|March 23, 2019
The BDNF<sub>Val66Met</sub> SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's diseaseNicolai Franzmeier, Jinyi Ren, Alexander Damm, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 21, 2024
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stageNelly Joseph-Mathurin, Rebecca L Feldman, Ruijin Lu, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Nature Medicine|June 18, 2024
Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALSMadhurima Chatterjee, Selcuk Özdemir, Christian Fritz, et al.
Journal of Alzheimer'S Disease : JAD|November 14, 2025
Associations of lifestyle factors with amyloid pathology in persons without dementiaJulie E Oomens, Stephanie Jb Vos, Nancy N Maserejian, et al.
JAMA Psychiatry|January 22, 2025
Depressive Symptoms and Amyloid PathologyWietse A Wiels, Julie E Oomens, Sebastiaan Engelborghs, et al.
Pageof 40

Showing results (381-390 of 391) with videos related to

Sort By:
Pageof 40
Neurology|January 26, 2021
Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Guoqiao Wang, Kejal Kantarci, et al.
Nature Neuroscience|July 10, 2023
Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)Nicole S McKay, Brian A Gordon, Russ C Hornbeck, et al.
Molecular Psychiatry|March 23, 2019
The BDNF<sub>Val66Met</sub> SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's diseaseNicolai Franzmeier, Jinyi Ren, Alexander Damm, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 21, 2024
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stageNelly Joseph-Mathurin, Rebecca L Feldman, Ruijin Lu, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Nature Medicine|June 18, 2024
Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALSMadhurima Chatterjee, Selcuk Özdemir, Christian Fritz, et al.
Journal of Alzheimer'S Disease : JAD|November 14, 2025
Associations of lifestyle factors with amyloid pathology in persons without dementiaJulie E Oomens, Stephanie Jb Vos, Nancy N Maserejian, et al.
JAMA Psychiatry|January 22, 2025
Depressive Symptoms and Amyloid PathologyWietse A Wiels, Julie E Oomens, Sebastiaan Engelborghs, et al.
Pageof 40